/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MLYS.O

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$39.15 0.0013(0.13%) MLYS at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 39.16
Highest Today 40.58
Today’s Open 39.29
Prev. Close 39.15
52 Week High 47.65
52 Week Low 8.24
Day’s Range: Low 39.16 High 40.58
52-Week Range: Low 8.24 High 47.65
1 day return -
1 Week return -9.23
1 month return -1.65
3 month return +18.2
6 month return +152.96
1 year return +213.17
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3098.33 M

PB Ratio 5.9201

PE Ratio 0.0

Enterprise Value 2818.89 M

Total Assets 205.90 M

Volume 2284050

Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-177810000 -177.8M, FY23:-56582000 -56.6M, FY22:-29799000 -29.8M, FY21:-19408000 -19.4M, FY20:-3426000 -3.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:-15000 -0.0M, Q2/2025:-16000 -0.0M, Q1/2025:-15000 -0.0M, Q4/2024:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q3/2025:-36932000 -36.9M, Q2/2025:-43274000 -43.3M, Q1/2025:-42211000 -42.2M, Q4/2024:-48946000 -48.9M, Q3/2024:-56342000 -56.3M

Fund house & investment objective

Company Information Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Organisation Biotechnology

Employees 51

Industry Biotechnology

CEO Mr. Jon Congleton

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow